Trial
NCT02630251
Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Cancer
Intervention
GSK2820151
Why stopped
In 2017, GSK2820151 was terminated due to development of another BET Inhibitor (GSK525762) with a better understanding of the risk benefit profile.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-02-12